New Guide Tackles Best Practices for Making Allogeneic Cell Therapies

07 June, 2024
Erich H. Bozenhardt
Associate Director Process Engineering, Regenerative Medicine
United Therapeutics

Erich Bozenhardt, Associate Director of Process Engineering and Therapeutics for United Therapeutics, an active ISPE member, and close collaborator on the ISPE Guide: Advanced Therapy Medicinal Products – Allogeneic Cell Therapy, has participated in an interview with Cell & Gene in which he shares insights on the new ISPE Guide. In the interview, Bozenhardt touches on the current state of manufacturing standards for allogeneic cell therapies, key differences between allogeneic advanced therapy medicinal products (ATMPs) and a typical aseptically manufactured biologic, and how the ISPE Guide approaches de-risking for more risk-heavy steps such as downstream during fill/finish.

Read the full article.

Guide: ATMPs - Allogeneic Cell Therapy

View more on the ISPE Guides.

About Cell & Gene

Cell & Gene delivers in-depth content about cell and gene therapies from experienced professionals in the field. This publication focuses exclusively on this segment of the life sciences industry.